Larsen & Toubro (L&T), one of India’s largest engineering and construction conglomerates, has secured significant engineering, procurement, and construction (EPC) contracts from the Public Health Engineering Department of Rajasthan. The cumulative value of these contracts is estimated between Rs. 1,000 crore and Rs. 2,500 crore, falling under the company’s classification of “significant” orders. The scope of the awarded projects includes extensive infrastructure for rural water supply, fluorosis mitigation, and system rehabilitation across multiple districts.

Aequs, a global precision manufacturing firm specializing in aerospace and consumer durables, has confidentially filed draft IPO documents with the Securities and Exchange Board of India (SEBI), targeting a raise of approximately USD 200 million (around Rs. 1,660 crore). The offering includes both a fresh issue of shares and an Offer For Sale (OFS) component. Leveraging the flexibility of SEBI’s pre-filing route, the company aims to optimize timing and disclosures while strengthening its public market debut.

Widespread flooding and landslides in the northeastern states of Assam, Sikkim, and Manipur have left tens of thousands displaced, caused significant infrastructural damage, and claimed multiple lives. With relentless rainfall overwhelming local systems, state authorities are engaged in extensive relief efforts. Prime Minister Narendra Modi has personally reached out to the chief ministers of the affected states, assuring full support from the central government.

India is witnessing a resurgence in COVID-19 cases, with active infections surpassing the 4,000 mark within a span of three days. The southern states of Kerala, Maharashtra, and Gujarat are reporting the highest number of new cases. The Ministry of Health and Family Welfare has confirmed five new fatalities, all involving individuals with underlying health conditions. This uptick in cases has prompted renewed vigilance and preventive measures across the country.

Thinkink Picturez, a prominent player in India’s media and entertainment sector, has appointed Chetan Chauhan as its new Chief Executive Officer. With close to three decades of experience in the industry, Chauhan is expected to lead the company’s strategic push into regional cinema. The studio plans to create content across multiple Indian languages including Gujarati and Marathi, reflecting a broader industry trend toward tapping into non-metro narratives.

In a call for heightened vigilance and innovation, Revenue Secretary Arvind Shrivastava emphasized the need for the Directorate of Revenue Intelligence (DRI) to adopt advanced technological tools and data-driven intelligence to counter evolving threats such as disguised supply chains, cross-border e-commerce fraud, and illicit activities on the dark web.

Emerging diversified construction companies in India are projected to experience stable revenue growth of 9-11% during fiscal year 2025-26, according to Crisil Ratings. Supported by robust order books and efficient project execution, these firms are scaling operations steadily, albeit at a slower pace compared to a five-year compounded annual growth rate of 15%. Operating margins are expected to remain constrained at 10-11% due to commodity price volatility and intensifying competition.

Biocon has obtained approval from the Drugs Controller General of India (DCGI) for its generic version of Liraglutide, a medication used to manage Type 2 Diabetes Mellitus across various age groups. This regulatory milestone, covering both the active drug substance and the injectable drug product through its subsidiary Biocon Pharma, marks a significant advance in the company’s mission to enhance treatment accessibility in India—home to over 77 million diabetes patients.

Indoco Remedies has taken a strategic step to enhance its presence in the UK pharmaceutical market through its subsidiary, Indoco Remedies UK Ltd, with the launch of Ticagrelor 90mg film-coated tablets. This generic medication is designed to reduce the risk of heart attacks, strokes, and other cardiovascular events. Marketed and distributed by Clarity Pharma, this launch aligns with Indoco’s commitment to providing high-quality, affordable, and life-saving treatments.

In the fiscal year 2024–25, Infosys CEO and Managing Director, Salil Parekh, received a total compensation of ₹80.62 crore, marking a 21.6% increase from the previous year. This remuneration comprises a base salary, performance bonuses, and substantial gains from stock options. Despite a modest rise in the company's net profit and a slight dip in quarterly earnings, Parekh's compensation underscores Infosys's commitment to rewarding leadership excellence.